Breaking News

Artielle, QSV Sign cGMP Contract for MS Drug

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

QSV Biologics, Ltd. and Artielle ImmunoTherapeutics, Inc. have signed a contract for the process development and cGMP manufacturing of RTL 1000 for multiple sclerosis. QSV will be responsible for technology transfer, process development and cGMP manufacture of Phase II/III trial material. RTL 1000, licensed by Artielle from Oregon Health & Science University, is a Recombinant T cell receptor Ligand (RTL) that can treat a wide range of autoimmune diseases. Graeme Macaloney Ph.D., PEng, ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters